Speaker: Jenna Frame, Senior Scientist, Scientific Communications

• Mice expressing human immune checkpoints can serve as powerful preclinical models to evaluate the in vivo efficacy of anti-human antibody candidates for immuno-oncology targets.
• Biocytogen’s humanized mice have been carefully designed and subjected to rigorous validation to ensure the integrity of immune responses.
• Biocytogen’s humanized CD3E & CD3EDG models allow for broader targeting of the entire CD3 complex with novel mono- & bispecific antibody therapeutics